192 related articles for article (PubMed ID: 25205109)
1. Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease.
Gratuze M; Noël A; Julien C; Cisbani G; Milot-Rousseau P; Morin F; Dickler M; Goupil C; Bezeau F; Poitras I; Bissonnette S; Whittington RA; Hébert SS; Cicchetti F; Parker JA; Samadi P; Planel E
Hum Mol Genet; 2015 Jan; 24(1):86-99. PubMed ID: 25205109
[TBL] [Abstract][Full Text] [Related]
2. Mutant huntingtin alters Tau phosphorylation and subcellular distribution.
Blum D; Herrera F; Francelle L; Mendes T; Basquin M; Obriot H; Demeyer D; Sergeant N; Gerhardt E; Brouillet E; Buée L; Outeiro TF
Hum Mol Genet; 2015 Jan; 24(1):76-85. PubMed ID: 25143394
[TBL] [Abstract][Full Text] [Related]
3. Implications of Tau Dysregulation in Huntington's Disease and Potential for New Therapeutics.
Mees I; Nisbet RM; Hannan AJ; Renoir T
J Huntingtons Dis; 2023; 12(1):1-13. PubMed ID: 37092231
[TBL] [Abstract][Full Text] [Related]
4. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.
Hsiao HY; Chen YC; Chen HM; Tu PH; Chern Y
Hum Mol Genet; 2013 May; 22(9):1826-42. PubMed ID: 23372043
[TBL] [Abstract][Full Text] [Related]
5. Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.
Saavedra A; Giralt A; Rué L; Xifró X; Xu J; Ortega Z; Lucas JJ; Lombroso PJ; Alberch J; Pérez-Navarro E
J Neurosci; 2011 Jun; 31(22):8150-62. PubMed ID: 21632937
[TBL] [Abstract][Full Text] [Related]
6. Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.
Choudhury KR; Das S; Bhattacharyya NP
J Proteomics; 2016 Jan; 132():155-66. PubMed ID: 26581643
[TBL] [Abstract][Full Text] [Related]
7. Passive immunization against phosphorylated tau improves features of Huntington's disease pathology.
Alpaugh M; Masnata M; de Rus Jacquet A; Lepinay E; Denis HL; Saint-Pierre M; Davies P; Planel E; Cicchetti F
Mol Ther; 2022 Apr; 30(4):1500-1522. PubMed ID: 35051614
[TBL] [Abstract][Full Text] [Related]
8. Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington's disease.
Ribeiro FM; Devries RA; Hamilton A; Guimaraes IM; Cregan SP; Pires RG; Ferguson SS
Hum Mol Genet; 2014 Apr; 23(8):2030-42. PubMed ID: 24282028
[TBL] [Abstract][Full Text] [Related]
9. Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease.
Pineda JR; Pardo R; Zala D; Yu H; Humbert S; Saudou F
Mol Brain; 2009 Oct; 2():33. PubMed ID: 19860865
[TBL] [Abstract][Full Text] [Related]
10. GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: involvement of astrocyte-neuron interactions.
L'Episcopo F; Drouin-Ouellet J; Tirolo C; Pulvirenti A; Giugno R; Testa N; Caniglia S; Serapide MF; Cisbani G; Barker RA; Cicchetti F; Marchetti B
Cell Death Dis; 2016 Apr; 7(4):e2206. PubMed ID: 27124580
[TBL] [Abstract][Full Text] [Related]
11. Interaction of huntingtin fragments with brain membranes--clues to early dysfunction in Huntington's disease.
Suopanki J; Götz C; Lutsch G; Schiller J; Harjes P; Herrmann A; Wanker EE
J Neurochem; 2006 Feb; 96(3):870-84. PubMed ID: 16405500
[TBL] [Abstract][Full Text] [Related]
12. Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism.
Wong HK; Bauer PO; Kurosawa M; Goswami A; Washizu C; Machida Y; Tosaki A; Yamada M; Knöpfel T; Nakamura T; Nukina N
Hum Mol Genet; 2008 Oct; 17(20):3223-35. PubMed ID: 18658163
[TBL] [Abstract][Full Text] [Related]
13. Global changes to the ubiquitin system in Huntington's disease.
Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
[TBL] [Abstract][Full Text] [Related]
14. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells.
Xifró X; García-Martínez JM; Del Toro D; Alberch J; Pérez-Navarro E
J Neurochem; 2008 Jun; 105(5):1596-612. PubMed ID: 18221365
[TBL] [Abstract][Full Text] [Related]
15. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
Padmanabhan J; Levy M; Dickson DW; Potter H
Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of tau pathologies in Huntington's disease.
Baskota SU; Lopez OL; Greenamyre JT; Kofler J
Lab Invest; 2019 Jul; 99(7):1068-1077. PubMed ID: 30573872
[TBL] [Abstract][Full Text] [Related]
17. Is Huntington's disease a tauopathy?
Gratuze M; Cisbani G; Cicchetti F; Planel E
Brain; 2016 Apr; 139(Pt 4):1014-25. PubMed ID: 26969684
[TBL] [Abstract][Full Text] [Related]
18. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
Fox JH; Barber DS; Singh B; Zucker B; Swindell MK; Norflus F; Buzescu R; Chopra R; Ferrante RJ; Kazantsev A; Hersch SM
J Neurochem; 2004 Oct; 91(2):413-22. PubMed ID: 15447674
[TBL] [Abstract][Full Text] [Related]
19. Hypothermia mediates age-dependent increase of tau phosphorylation in db/db mice.
El Khoury NB; Gratuze M; Petry F; Papon MA; Julien C; Marcouiller F; Morin F; Nicholls SB; Calon F; Hébert SS; Marette A; Planel E
Neurobiol Dis; 2016 Apr; 88():55-65. PubMed ID: 26777665
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of calcineurin by infusion of CsA causes hyperphosphorylation of tau and is accompanied by abnormal behavior in mice.
Yu DY; Luo J; Bu F; Song GJ; Zhang LQ; Wei Q
Biol Chem; 2006 Jul; 387(7):977-83. PubMed ID: 16913847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
